The need for pharmacotherapy among patients with one or more elevations on glucose tolerance test
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgag062 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Lizelle Comfort und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Northwell, New Hyde Park, NY 11042, USA. Hauptthemen laut MEDLINE: Diabetes, Gestational, Hypoglycemic Agents, Glucose Intolerance. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To identify factors associated with need for pharmacotherapy among patients with glucose intolerance and 1 elevation on 3-hour oral glucose tolerance test (OGTT).
Methods
Retrospective cohort study of singleton gestations 24 weeks or greater with at least 1 elevation on OGTT. The primary outcome was need for pharmacotherapy for glycemic control. To evaluate timing of OGTT elevation with need for pharmacotherapy, a logistic regression model controlled for maternal race/ethnicity, body mass index (BMI), gestational age at time of OGTT, age, parity, history of gestational diabetes, and history of large neonate. The need for pharmacotherapy was assessed based on number and extent of testing elevations. A predictive model based on linear discriminant analysis was developed.
Results
Overall, 480 patients had 1 OGTT elevation; of these, 19.2% required pharmacotherapy. Fasting elevations were most associated with development of medication-requiring diabetes. A predictive model for risk of pharmacotherapy in patients with an abnormal OGTT based on BMI and extent of elevation at each OGTT time point increased the identification of patients requiring pharmacotherapy by 15.4%. At least 2 OGTT elevations occurred in 376 patients; these patients were more likely to require pharmacotherapy for glycemic control compared to those with 1 elevation. Patients with increasing BMI values had increased need for pharmacotherapy regardless of the number of abnormal values.
Conclusion
Among patients with 1 OGTT elevation, fasting elevation and BMI are predictive of need for anti-glycemic medications. Predictive models may be useful in assessing need for pharmacotherapy for patients with abnormal OGTT, not otherwise meeting criteria for gestational diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Northwell, New Hyde Park, NY 11042, USA.
- Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA.
ORCID-Profile: Lizelle Comfort, Alexis Benjamin, Emma Brenner, David Krantz, Heather Levin, Burton Rochelson
Zitieren
APA
Comfort, L., Benjamin, A., Brenner, E., Krantz, D., Bonanno, C., Levin, H., Faizullabhoy, A., & Rochelson, B. (2026). The need for pharmacotherapy among patients with one or more elevations on glucose tolerance test. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag062
Vancouver
Comfort L, Benjamin A, Brenner E, Krantz D, Bonanno C, Levin H, et al. The need for pharmacotherapy among patients with one or more elevations on glucose tolerance test. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag062
BibTeX
@article{Comfort2026,
author = {Comfort, Lizelle and Benjamin, Alexis and Brenner, Emma and Krantz, David and Bonanno, Clarissa and Levin, Heather and Faizullabhoy, Alefiya and Rochelson, Burton},
title = {The need for pharmacotherapy among patients with one or more elevations on glucose tolerance test},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag062}
}
EUVIMED